Armistice Capital’s VolitionRx Ltd VNRX Stock Holding History

Armistice Capital’s Portfolio VNRX Stock Details VNRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-469,021	Closed	-$6.37M	–	491
2025 Q3	$6.37M	Buy	469,021 +44,367	+10%	+$590K	0.09%	101
2025 Q2	$6.45M	Buy	424,654 +14,332	+3%	+$158K	0.11%	87
2025 Q1	$4.68M	Sell	410,322 -13,773	-3%	-$164K	0.07%	117
2024 Q4	$5.09M	Sell	424,095 -25,841	-6%	-$347K	0.07%	122
2024 Q3	$5.41M	Buy	+449,936	New	+$5.79M	0.09%	119

Other funds holding VNRX

LIM

Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

SBCM

Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Armistice Capital's VNRX Position: Q4 2025 in Review

Armistice Capital sold out of VolitionRx Ltd (VNRX) in Q4 2025, closing a stake of 469,021 shares — an estimated $6.37M sold.

Armistice Capital first reported a position in VNRX in Q3 2024 and held it in 5 quarters. The position peaked at $6.45M in Q2 2025. 28 funds tracked by Wall St. Rank hold VNRX as of Q4 2025.

Armistice Capital reported no remaining VolitionRx Ltd position as of Q4 2025 after selling out during the quarter.
Armistice Capital sold 469,021 VolitionRx Ltd shares in Q4 2025, an estimated $6.37M.
Armistice Capital first reported a position in VolitionRx Ltd in Q3 2024 and held it in 5 quarters.
Armistice Capital's VolitionRx Ltd position peaked at $6.45M in Q2 2025.
28 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q4 2025.

Based on Armistice Capital's 13F filing for Q4 2025, filed 17 Feb 2026.